HYCAMTIN 4MG I.V. VIAL 4 mg Powder for concentrate for solution for infusion Vial

Product Overview

HYCAMTIN 4mg I.V. Vial is a potent antineoplastic agent designed for intravenous administration.
It contains 4 mg of Topotecan, a critical active ingredient in the fight against various cancers.
This medication is presented as a powder for concentrate, which is then reconstituted to form a solution for infusion.

Product Details

HYCAMTIN (Topotecan) is a topoisomerase I inhibitor, a class of chemotherapeutic agents that interfere with DNA replication in cancer cells.
It is specifically indicated for the treatment of metastatic carcinoma of the ovary after failure of prior chemotherapy.
Additionally, it is used for small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy.
In some protocols, it is also used for advanced cervical cancer.
Each vial is formulated to ensure precise dosage and efficacy when prepared and administered by qualified medical personnel.

Benefits of Use

Using HYCAMTIN 4mg I.V. Vial offers several key benefits in oncology treatment:

• Targeted action against cancer cells by inhibiting topoisomerase I, crucial for DNA replication.
• Established efficacy in treating specific types of advanced cancers, including ovarian, small cell lung, and cervical cancers.
• Provides a vital treatment option for patients who have not responded to or have relapsed after initial chemotherapy regimens.
• Contributes to disease control and potential improvement in patient outcomes in appropriate clinical settings.

How to Use

HYCAMTIN 4mg I.V. Vial must be prepared and administered by a healthcare professional experienced in the use of antineoplastic agents. The general steps involve:

1. Verify the correct dose based on the patient's body surface area and treatment protocol.
2. Reconstitute the HYCAMTIN powder with the specified volume of sterile water for injection according to manufacturer instructions.
3. Further dilute the reconstituted solution in either 0.9% sodium chloride injection or 5% dextrose injection to the appropriate final concentration.
4. Administer the diluted solution via intravenous infusion over a recommended period, typically 30 minutes, daily for 5 consecutive days, or as per specific treatment regimen.
5. Closely monitor the patient for adverse reactions during and after infusion.

Caution & Warnings

• Severe Myelosuppression: HYCAMTIN can cause severe bone marrow suppression, leading to neutropenia (low white blood cell count), thrombocytopenia (low platelet count), and anemia (low red blood cell count). Regular monitoring of complete blood counts is essential.
• Infections: Due to myelosuppression, patients are at increased risk of serious infections, including sepsis, which can be fatal.
• Nausea, Vomiting, Diarrhea: These gastrointestinal side effects are common and may require antiemetic and antidiarrheal support.
• Fatigue and Weakness: Patients often experience significant fatigue during treatment.
• Alopecia: Hair loss is a common side effect.
• Pregnancy and Lactation: HYCAMTIN can cause fetal harm and is contraindicated in pregnant or breastfeeding women. Effective contraception should be used by patients of reproductive potential.
• Extravasation: Care should be taken to avoid extravasation (leakage of the drug into surrounding tissue) during administration.
• Renal Impairment: Dose adjustments may be necessary for patients with impaired renal function.

Ingredients

Each vial of HYCAMTIN 4mg contains:

• Active Ingredient: Topotecan hydrochloride equivalent to 4 mg Topotecan
• Excipients: Mannitol, Tartaric acid